NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

2017 A/H7N9 IIV Revaccination

Phase 2

Completed

Conditions: Avian Influenza
Influenza Immunisation

Interventions: Biological: A/H7N9
Drug: AS03
Other: Phosphate Buffered Saline (PBS) diluent

First Posted Date: 2018-11-13

Last Posted Date: 2021-07-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 304

Registration Number: NCT03738241

Locations: 🇺🇸
Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States
🇺🇸
The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD), Galveston, Texas, United States
🇺🇸
Emory Children's Center - Pediatric Infectious Diseases, Atlanta, Georgia, United States

and more 6 locations

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: VRC07-523LS

First Posted Date: 2018-11-08

Last Posted Date: 2022-03-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 28

Registration Number: NCT03735849

Locations: 🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸
Seattle Vaccine and Prevention CRS, Seattle, Washington, United States

PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)

Active, not recruiting

Conditions: HIV

First Posted Date: 2018-11-07

Last Posted Date: 2024-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1377

Registration Number: NCT03733093

Locations: 🇱🇷
Redemption Hospital, Monrovia, Liberia
🇱🇷
C.H. Rennie Hospital, Kakata, Liberia
🇱🇷
John F. Kennedy (JFK) Medical Center, Monrovia, Liberia

and more 1 locations

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

Phase 1

Withdrawn

Conditions: CTLA4 Haploinsufficency
Chronic Cytopenia

Interventions: Drug: abatacept
Other: Placebo

First Posted Date: 2018-11-07

Last Posted Date: 2023-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT03733067

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study

Phase 1

Recruiting

Conditions: Renal Transplant Recipients
Kidney Transplant

First Posted Date: 2018-10-31

Last Posted Date: 2023-07-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 28

Registration Number: NCT03726307

Locations: 🇺🇸
University of Pittsburgh, Starzl Transplantation Institute, Pittsburgh, Pennsylvania, United States

Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

Phase 2

Completed

Conditions: Ebola Virus

Interventions: Drug: MAb114
Drug: REGN-EB3
Drug: ZMapp
Drug: Remdesivir

First Posted Date: 2018-10-25

Last Posted Date: 2021-09-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 681

Registration Number: NCT03719586

Locations: 🇨🇩
Ebola Treatment Centers throughout the DRC, Kinshasa Gombe, Congo, The Democratic Republic of the
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia

Completed

Conditions: Malaria

First Posted Date: 2018-10-25

Last Posted Date: 2024-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1264

Registration Number: NCT03719599

Locations: 🇱🇷
C.H. Rennie Hospital, Margibi, Liberia
🇱🇷
Duport Road Health Center, Monrovia, Liberia

Dual bNAb Treatment in Children

Phase 1

Completed

Conditions: HIV Infection

Interventions: Drug: ART
Biological: VRC01LS
Biological: 10-1074

First Posted Date: 2018-10-16

Last Posted Date: 2024-10-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT03707977

Locations: 🇧🇼
Francistown Non-Network CRS, Francistown, Botswana
🇧🇼
Botswana Harvard AIDS Institute Partnership CRS Non-Network, Gaborone, Botswana

Pharmacokinetics and Safety of SAR441236

Phase 1

Terminated

Conditions: HIV-1-infection

Interventions: Biological: SAR441236
Biological: Placebo

First Posted Date: 2018-10-15

Last Posted Date: 2024-01-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT03705169

Locations: 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸
Case Clinical Research Site, Cleveland, Ohio, United States
🇺🇸
Northwestern University CRS, Chicago, Illinois, United States

and more 20 locations

Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)

Phase 4

Terminated

Conditions: Urinary Tract Infection

Interventions: Drug: Fosfomycin tromethamine
Drug: Levofloxacin

First Posted Date: 2018-10-05

Last Posted Date: 2020-12-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT03697993

Locations: 🇺🇸
Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States
🇺🇸
Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
University of California Los Angeles - Olive View Medical Center, Sylmar, California, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy